While a larger scale analysis of the whole transcriptome undoubtedly requires higher (at least six) replicates, we have embarked on an idea that downsizing into select genes would allow immediate screens of the unknown such as ZCCHC8 as compared to a widely investigated gene like APP, given the repetitive failures of clinical trials for therapies of AD (Anderson et al., 2017). The gene discussed is APP; the disease is Alzheimer disease.